Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with menopause, after Astellas' Veoza was cleared for NHS use.

Novo Nordisk has been sent a warning letter from the FDA for a series of violations of postmarketing adverse drug experience (PADE) regulations, including failure to report side effects among patients ...

Genmab's recently approved therapy for cervical cancer that has come back or spread, Tivdak, has been turned down for NHS use in initial guidance from reimbursement authority NICE. Tivdak (tisotumab ...

The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida. Designed as an ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

Veeva Systems has built its presence in brand engagement with the acquisition of Ostro, a tech startup that helps pharma companies connect with doctors and patients using AI-powered conversational ...

Moderna has agreed to settle litigation with Arbutus Biopharma and Roivant's Genevant that claimed its blockbuster COVID-19 vaccine infringed patents, with an upfront payment of $950 million. Arbutus ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma. Alnylam is broadening its position in the area of RNA interference ...

An international group of cancer experts has called for fundamental change to healthcare approaches for bile duct cancer, which kills three-quarters of patients within a year of diagnosis. The group ...

The Centers for Medicare & Medicaid Services (CMS) in the US has extended the deadline for companies to take part in its GENEROUS pilot programme, designed to implement Most-Favoured Nation (MFN) ...

New research has lent weight to the intriguing idea that GLP-1 agonists may have a role to play in helping people with substance use disorders (SUD) break their addiction. A meta-analysis carried out ...

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year, but two of them far outstrip the others in sales ...